IN3BIO gains approval for Phase I/II clinical trial

10 June 2021 | Thursday | News


IN3BIO Research Limited announced today that the company has received the Clinical Trial Application approval from the Bulgarian Drug Agency and Ethical Committee to initiate a Phase I/II clinical trial of its colorectal cancer vaccine in Bulgaria.

IN3BIO will trial its innovative anti-EGF vaccine IN01, in combination with small molecule inhibitors (SMIs) in patients suffering from KRAS or NRAS (Cohort A) or BRAF (Cohort B) mutated colorectal cancer.


Erik D'Hondt, CEO of IN3BIO said "We are delighted to have reached this significant regulatory step to conduct our clinical trial in Bulgaria. This first approval will lead to patients being enrolled rapidly in centres in Bulgaria, then in clinical centres in other EU and non-EU countries".

News

Stay Connected

Sign up to our free newsletter and get the latest news sent direct to your inbox

Show

Forgot your password?

Show

Show

Lost your password? Please enter your email address. You will receive a link to create a new password.

Back to log-in

Close